enVVeno Medical (NVNO) has shared an update.
EnVVeno Medical Corporation has revealed promising topline efficacy data from its SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum in Tampa, indicating significant clinical improvement. The announcement emphasizes that while these forward-looking statements show the company’s expectations for the future, they involve risks and uncertainties that could cause actual results to differ. The company reminds investors to consider these factors carefully, as detailed in their regulatory filings.
Find detailed analytics on NVNO stock on TipRanks’ Stock Analysis page.
